Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Servies, Bethesda, Maryland, United States of America.
PLoS One. 2012;7(7):e40204. doi: 10.1371/journal.pone.0040204. Epub 2012 Jul 5.
Vitamin E compounds exhibit prostate cancer preventive properties experimentally, but serologic investigations of tocopherols, and randomized controlled trials of supplementation in particular, have been inconsistent. Many studies suggest protective effects among smokers and for aggressive prostate cancer, however.
We conducted a nested case-control study of serum α-tocopherol and γ-tocopherol and prostate cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, with 680 prostate cancer cases and 824 frequency-matched controls. Multivariate-adjusted, conditional logistic regression models were used to estimate odds ratios (OR) and 95% confidence intervals (CIs) for tocopherol quintiles.
Serum α-tocopherol and γ-tocopherol were inversely correlated (r = -0.24, p<0.0001). Higher serum α-tocopherol was associated with significantly lower prostate cancer risk (OR for the highest vs. lowest quintile = 0.63, 95% CI 0.44-0.92, p-trend 0.05). By contrast, risk was non-significantly elevated among men with higher γ-tocopherol concentrations (OR for the highest vs. lowest quintile = 1.35, 95% CI 0.92-1.97, p-trend 0.41). The inverse association between prostate cancer and α-tocopherol was restricted to current and recently former smokers, but was only slightly stronger for aggressive disease. By contrast, the increased risk for higher γ-tocopherol was more pronounced for less aggressive cancers.
Our findings indicate higher α-tocopherol status is associated with decreased risk of developing prostate cancer, particularly among smokers. Although two recent controlled trials did not substantiate an earlier finding of lower prostate cancer incidence and mortality in response to supplementation with a relatively low dose of α-tocopherol, higher α-tocopherol status may be beneficial with respect to prostate cancer risk among smokers. Determining what stage of prostate cancer development is impacted by vitamin E, the underlying mechanisms, and how smoking modifies the association, is needed for a more complete understanding of the vitamin E-prostate cancer relation.
维生素 E 化合物在实验中表现出预防前列腺癌的特性,但有关生育酚的血清学研究,特别是补充剂的随机对照试验,结果并不一致。然而,许多研究表明,生育酚对吸烟者和侵袭性前列腺癌具有保护作用。
我们在前列腺癌、肺癌、结直肠癌和卵巢癌筛查试验中进行了一项病例对照嵌套研究,分析了血清α-生育酚和γ-生育酚与前列腺癌风险的关系,共纳入了 680 例前列腺癌病例和 824 例频数匹配对照。采用多变量调整的条件逻辑回归模型来估计生育酚五分位的比值比(OR)和 95%置信区间(CI)。
血清α-生育酚和γ-生育酚呈负相关(r=-0.24,p<0.0001)。血清α-生育酚水平越高,前列腺癌风险越低(最高五分位与最低五分位相比的 OR=0.63,95%CI 0.44-0.92,p-trend=0.05)。相反,γ-生育酚浓度较高的男性前列腺癌风险非显著升高(最高五分位与最低五分位相比的 OR=1.35,95%CI 0.92-1.97,p-trend=0.41)。α-生育酚与前列腺癌之间的负相关仅局限于当前和近期的吸烟者,但对于侵袭性疾病,这种相关性略强。相比之下,γ-生育酚与较高风险之间的关联对于侵袭性较低的癌症更为明显。
我们的研究结果表明,较高的α-生育酚状态与前列腺癌风险降低相关,特别是在吸烟者中。尽管最近的两项对照试验未能证实早期发现的低剂量α-生育酚补充可降低前列腺癌的发病率和死亡率,但较高的α-生育酚状态可能对吸烟者的前列腺癌风险有益。为了更全面地了解维生素 E 与前列腺癌的关系,需要确定维生素 E 对前列腺癌发展的哪个阶段有影响、潜在的机制以及吸烟如何改变这种关联。